Table 4 Baseline predictors of osteoporosis-related fractures overall in the full RA cohort*

Age, per 10 years

3.59

(2.52; 5.12)

NA

2.32

(1.99; 2.71)

NA

2.51

(2.18; 2.90)

NA

RA duration, per 10 years

1.49

(1.19; 1.87)

1.23

(0.99; 1.51)

1.23

(1.09; 1.39)

1.08

(0.96; 1.21)

1.28

(1.15; 1.43)

1.11

(1.00; 1.22)

RF-positive

1.02

(0.46; 2.23)

1.76

(0.79; 3.90)

NA¹

NA¹

1.07

(0.74; 1.53)

1.34

(0.93; 1.93)

HAQ, per SD

1.68

(1.20; 2.34)

1.40

(0.99; 1.96)

1.36

(1.14; 1.63)

1.11

(0.93; 1.33)

1.45

(1.24; 1.69)

1.20

(1.03; 1.40)

VAS pain, per SD

1.19

(0.86; 1.65)

1.31

(0.96; 1.80)

1.07

(0.90; 1.27)

1.01

(0.85; 1.20)

1.11

(0.96; 1.29)

1.10

(0.94; 1.28)

VAS global health, per SD

1.36

(0.98; 1.89)

1.55

(1.11; 2.15)

1.20

(1.01; 1.43)

1.10

(0.93; 1.32)

1.25

(1.08; 1.46)

1.20

(1.03; 1.40)

Methotrexate

NA¹

NA¹

0.84

(0.60; 1.17)

0.93

(0.66; 1.30)

NA¹

NA¹

bDMARDs

0.24

(0.03; 1.77)

0.65

(0.09; 4.85)

0.47

(0.22; 1.01)

1.01

(0.46; 2.19)

0.41

(0.20; 0.85)

0.90

(0.44; 1.85)

Prednisolone

1.68

(0.84; 3.34)

1.78

(0.88; 3.61)

1.56

(1.09; 2.23)

1.24

(0.86; 1.77)

1.58

(1.16; 2.17)

1.31

(0.95; 1.80)